Replies to post #33383 on Humanigen Inc (fka HGENQ)

[ohm20]

Not much in the ole clinical trial pipeline and the only other in phase 2/3 is GVHD which is low revenue. There's a reason why Cytodyn abandoned it in favor of more lucrative diseases. Although I'm sure they'll get back to it when the revenue piles up. Everything listed in that pipeline leronlimab can cover and do it better.

Interesting though that you see a higher value of HGEN in a failure state than CYDY in it's current failure state.

HGEN's market cap at $2.50 would be $148 million. I think Cytodyn's current market cap beats that. It even beats HGEN's current $361 million. The market certainly thinks CYDY is more valuable then HGEN.